In December 2023, COACH convened its seventh meeting with representatives from the National Cancer Institute (NCI), Food and Drug Administration (FDA), European Medicines Agency (EMA), advocacy groups, the pharmaceutical industry, Pancreatic Preclinical Proof of Concept Platform (PCCP), and the Pediatric Preclinical Testing Working Group (PCTWG) to assess cancer-targeted agents that could be potential entities for development of life-saving drugs for pediatric indications.

### Key Considerations

**CCR8:**
- Is a cell surface receptor associated with immunosuppressive functions of tumor-infiltrating regulatory T cells (Tregs).
- CCR8 is primarily expressed on Tregs, RNA expression levels in both tumor tissue are low, and tumor-specific deletion of CCR8 has limited impact on viability.
- CCR8 monoclonal antibodies (mAbs) result in tumor-infiltrating Tregs, while selective CCR8 antagonists in healthy tissues, making it an appealing drug for targeting tumor-specific immunosuppressive mechanisms.

**HER2:**
- HER2 is a cell surface receptor associated with the mechanisms of action (MOAs) for HER2-targeting ADCs in treating tumors with high HER2 expression.
- HER2-targeting ADCs have shown rapid insights into the relevance of HER2-specific mechanisms.
- Antibody-drug conjugates (ADCs) have shown anti-tumor activity in preclinical glioma and osteosarcoma models, as well as prolonged survival and reduced tumor size in a preclinical model.

**Key Considerations**

**Clinical Development Status:**

- Appropriate drugs with EMA coordination for Phase I or clinical trials for key pediatric indications.
- Initial achievements worldwide advanced in Phase I or clinical trials for key pediatric indications.

**Clinical Development Status**

### Recommendations

**Clinical Development Status**

- Additional pediatric trials could provide insights into the activity, safety profiles, and TEAD subtype-specific outcomes.
- Clinical trials will provide insights into MOAs for other tumor types.
- Additional pediatric studies are needed to better understand the preclinical activity observed in HER2-targeted pediatric tumors and provide insights into MOAs for other tumor types.

**Clinical Development Status**

### References

[fnih.org/coach]